speb/financial-data huggingface dataset:
JBI balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 112000000.00
JBI cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Financing Activities: -18500000.00
JBI cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Investing Activities: -100000000.00
JBI cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Operating Activities: 36200000.00
JBI cash_flow (quarterly, 2026-03-31) — Change In Account Payable: 10300000.00
JBI cash_flow (quarterly, 2026-03-31) — Change In Accrued Expense: -2200000.00
JBI cash_flow (quarterly, 2026-03-31) — Change In Inventory: -1700000.00
JBI cash_flow (quarterly, 2026-03-31) — Change In Other Current Assets: 0.00
JBI cash_flow (quarterly, 2026-03-31) — Change In Other Working Capital: -2100000.00
JBI cash_flow (quarterly, 2026-03-31) — Change In Payable: 10300000.00
JBI cash_flow (quarterly, 2026-03-31) — Change In Payables And Accrued Expense: 8100000.00
JBI cash_flow (quarterly, 2026-03-31) — Change In Prepaid Assets: -2800000.00
JBI cash_flow (quarterly, 2026-03-31) — Change In Receivables: 7700000.00
JBI cash_flow (quarterly, 2026-03-31) — Change In Working Capital: 9200000.00
JBI cash_flow (quarterly, 2026-03-31) — Changes In Account Receivables: 10600000.00
JBI cash_flow (quarterly, 2026-03-31) — Changes In Cash: -82300000.00
JBI balance_sheet (quarterly, 2026-03-31) — Common Stock: 0.00
JBI balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 560100000.00
JBI cash_flow (quarterly, 2026-03-31) — Common Stock Payments: -15500000.00
JBI balance_sheet (quarterly, 2026-03-31) — Construction In Progress: 4500000.00
JBI income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 147500000.00
JBI balance_sheet (quarterly, 2026-03-31) — Current Accrued Expenses: 9600000.00
JBI balance_sheet (quarterly, 2026-03-31) — Current Assets: 355000000.00
JBI balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 6900000.00
JBI balance_sheet (quarterly, 2026-03-31) — Current Debt: 6300000.00
JBI balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 13200000.00
JBI balance_sheet (quarterly, 2026-03-31) — Current Deferred Liabilities: 33000000.00
JBI balance_sheet (quarterly, 2026-03-31) — Current Deferred Revenue: 33000000.00
JBI balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 134100000.00
JBI cash_flow (quarterly, 2026-03-31) — Deferred Income Tax: 1800000.00
JBI cash_flow (quarterly, 2026-03-31) — Deferred Tax: 1800000.00
JBI cash_flow (quarterly, 2026-03-31) — Depreciation: 3600000.00
JBI cash_flow (quarterly, 2026-03-31) — Depreciation Amortization Depletion: 15600000.00
JBI cash_flow (quarterly, 2026-03-31) — Depreciation And Amortization: 15600000.00
JBI income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 138774254.00
JBI income_statement (quarterly, 2026-03-31) — Diluted EPS: 0.00
JBI income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: 200000.00
JBI income_statement (quarterly, 2026-03-31) — EBIT: 10600000.00
JBI income_statement (quarterly, 2026-03-31) — EBITDA: 26200000.00
JBI cash_flow (quarterly, 2026-03-31) — Effect Of Exchange Rate Changes: -100000.00
JBI cash_flow (quarterly, 2026-03-31) — End Cash Position: 112000000.00
JBI cash_flow (quarterly, 2026-03-31) — Financing Cash Flow: -18500000.00
JBI balance_sheet (quarterly, 2026-03-31) — Finished Goods: 13800000.00
JBI cash_flow (quarterly, 2026-03-31) — Free Cash Flow: 33400000.00
JBI balance_sheet (quarterly, 2026-03-31) — Gains Losses Not Affecting Retained Earnings: -1600000.00
JBI income_statement (quarterly, 2026-03-31) — General And Administrative Expense: 44200000.00
JBI balance_sheet (quarterly, 2026-03-31) — Goodwill: 428000000.00
JBI balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 796900000.00
JBI balance_sheet (quarterly, 2026-03-31) — Gross Accounts Receivable: 123600000.00
JBI balance_sheet (quarterly, 2026-03-31) — Gross PPE: 196200000.00
JBI income_statement (quarterly, 2026-03-31) — Gross Profit: 75200000.00
JBI cash_flow (quarterly, 2026-03-31) — Income Tax Paid Supplemental Data: 100000.00
JBI balance_sheet (quarterly, 2026-03-31) — Income Tax Payable: 300000.00
JBI income_statement (quarterly, 2026-03-31) — Interest Expense: 8100000.00
JBI income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 8100000.00
JBI cash_flow (quarterly, 2026-03-31) — Interest Paid Supplemental Data: 6500000.00
JBI balance_sheet (quarterly, 2026-03-31) — Interest Payable: 5500000.00
JBI balance_sheet (quarterly, 2026-03-31) — Inventory: 61100000.00
JBI balance_sheet (quarterly, 2026-03-31) — Invested Capital: 1106800000.00
JBI cash_flow (quarterly, 2026-03-31) — Investing Cash Flow: -100000000.00
JBI balance_sheet (quarterly, 2026-03-31) — Land And Improvements: 900000.00
JBI balance_sheet (quarterly, 2026-03-31) — Leases: 13400000.00
JBI balance_sheet (quarterly, 2026-03-31) — Long Term Debt: 540400000.00
JBI balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 540400000.00
JBI cash_flow (quarterly, 2026-03-31) — Long Term Debt Payments: -400000.00
JBI balance_sheet (quarterly, 2026-03-31) — Machinery Furniture Equipment: 95600000.00
JBI cash_flow (quarterly, 2026-03-31) — Net Business Purchase And Sale: -97200000.00
JBI cash_flow (quarterly, 2026-03-31) — Net Common Stock Issuance: -15500000.00
JBI balance_sheet (quarterly, 2026-03-31) — Net Debt: 434700000.00
JBI income_statement (quarterly, 2026-03-31) — Net Income: 200000.00
JBI income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: 200000.00
JBI income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: 200000.00
JBI income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 200000.00
JBI income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 200000.00
JBI cash_flow (quarterly, 2026-03-31) — Net Income From Continuing Operations: 200000.00
JBI income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: 200000.00
JBI income_statement (quarterly, 2026-03-31) — Net Interest Income: -8100000.00
JBI cash_flow (quarterly, 2026-03-31) — Net Issuance Payments Of Debt: -400000.00
JBI cash_flow (quarterly, 2026-03-31) — Net Long Term Debt Issuance: -400000.00
JBI income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: -8100000.00
JBI cash_flow (quarterly, 2026-03-31) — Net Other Financing Charges: -2600000.00
JBI balance_sheet (quarterly, 2026-03-31) — Net PPE: 140600000.00
JBI cash_flow (quarterly, 2026-03-31) — Net PPE Purchase And Sale: -2800000.00
JBI balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: -236800000.00
JBI balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Assets: 11500000.00
JBI balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Liabilities: 3100000.00
JBI balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Assets: 11500000.00
JBI balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Liabilities: 3100000.00
JBI income_statement (quarterly, 2026-03-31) — Normalized EBITDA: 28300000.00
JBI income_statement (quarterly, 2026-03-31) — Normalized Income: 1460000.00
JBI cash_flow (quarterly, 2026-03-31) — Operating Cash Flow: 36200000.00
JBI cash_flow (quarterly, 2026-03-31) — Operating Gains Losses: 1000000.00
JBI income_statement (quarterly, 2026-03-31) — Operating Income: 13100000.00
JBI income_statement (quarterly, 2026-03-31) — Operating Revenue: 222700000.00
JBI balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 136392459.00
JBI balance_sheet (quarterly, 2026-03-31) — Other Current Assets: 24800000.00
JBI balance_sheet (quarterly, 2026-03-31) — Other Current Borrowings: 6300000.00
JBI balance_sheet (quarterly, 2026-03-31) — Other Current Liabilities: 8200000.00
JBI balance_sheet (quarterly, 2026-03-31) — Other Equity Adjustments: -1600000.00
JBI income_statement (quarterly, 2026-03-31) — Other Gand A: 44200000.00
JBI income_statement (quarterly, 2026-03-31) — Other Income Expense: -2500000.00
JBI balance_sheet (quarterly, 2026-03-31) — Other Intangible Assets: 368900000.00
JBI cash_flow (quarterly, 2026-03-31) — Other Non Cash Items: 3200000.00
JBI balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: 5100000.00
JBI balance_sheet (quarterly, 2026-03-31) — Other Non Current Liabilities: 71400000.00
JBI income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: -400000.00
JBI balance_sheet (quarterly, 2026-03-31) — Other Properties: 73400000.00
JBI balance_sheet (quarterly, 2026-03-31) — Other Receivables: 34200000.00
JBI income_statement (quarterly, 2026-03-31) — Other Special Charges: 2100000.00
JBI balance_sheet (quarterly, 2026-03-31) — Payables: 58600000.00
JBI balance_sheet (quarterly, 2026-03-31) — Payables And Accrued Expenses: 68200000.00
JBI balance_sheet (quarterly, 2026-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 11500000.00
JBI balance_sheet (quarterly, 2026-03-31) — Prepaid Assets: 11500000.00
JBI income_statement (quarterly, 2026-03-31) — Pretax Income: 2500000.00
JBI balance_sheet (quarterly, 2026-03-31) — Properties: 0.00
JBI cash_flow (quarterly, 2026-03-31) — Provisionand Write Offof Assets: 300000.00
JBI cash_flow (quarterly, 2026-03-31) — Purchase Of Business: -97200000.00
JBI cash_flow (quarterly, 2026-03-31) — Purchase Of PPE: -2800000.00
JBI balance_sheet (quarterly, 2026-03-31) — Raw Materials: 47000000.00
JBI balance_sheet (quarterly, 2026-03-31) — Receivables: 145600000.00
JBI income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 147500000.00
JBI income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 15600000.00
JBI cash_flow (quarterly, 2026-03-31) — Repayment Of Debt: -400000.00
JBI cash_flow (quarterly, 2026-03-31) — Repurchase Of Capital Stock: -15500000.00
JBI balance_sheet (quarterly, 2026-03-31) — Retained Earnings: 358300000.00
JBI income_statement (quarterly, 2026-03-31) — Selling And Marketing Expense: 17900000.00
JBI income_statement (quarterly, 2026-03-31) — Selling General And Administration: 62100000.00
JBI balance_sheet (quarterly, 2026-03-31) — Share Issued: 149089626.00
JBI income_statement (quarterly, 2026-03-31) — Special Income Charges: -2100000.00
JBI cash_flow (quarterly, 2026-03-31) — Stock Based Compensation: 4900000.00
JBI balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 560100000.00
JBI balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: -236800000.00
JBI income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: -840000.00
JBI income_statement (quarterly, 2026-03-31) — Tax Provision: 2300000.00
JBI income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.40
JBI balance_sheet (quarterly, 2026-03-31) — Total Assets: 1309100000.00
JBI balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 1100500000.00
JBI balance_sheet (quarterly, 2026-03-31) — Total Debt: 553600000.00
JBI balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 560100000.00
JBI income_statement (quarterly, 2026-03-31) — Total Expenses: 209600000.00
JBI balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 749000000.00
JBI balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 954100000.00
JBI balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 614900000.00
JBI income_statement (quarterly, 2026-03-31) — Total Operating Income As Reported: 13100000.00
JBI balance_sheet (quarterly, 2026-03-31) — Total Tax Payable: 3100000.00
JBI income_statement (quarterly, 2026-03-31) — Total Unusual Items: -2100000.00
JBI income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: -2100000.00
JBI balance_sheet (quarterly, 2026-03-31) — Treasury Shares Number: 12697167.00
JBI balance_sheet (quarterly, 2026-03-31) — Treasury Stock: 117400000.00
JBI balance_sheet (quarterly, 2026-03-31) — Work In Process: 300000.00
JBI balance_sheet (quarterly, 2026-03-31) — Working Capital: 220900000.00
JBIO balance_sheet (quarterly, 2024-09-30) — Accounts Payable: 923000.00
JBIO balance_sheet (quarterly, 2024-09-30) — Additional Paid In Capital: 3000.00
JBIO income_statement (quarterly, 2024-09-30) — Basic Average Shares: 32235926.00
JBIO income_statement (quarterly, 2024-09-30) — Basic EPS: -0.50
JBIO balance_sheet (quarterly, 2024-09-30) — Capital Stock: 1000.00
JBIO balance_sheet (quarterly, 2024-09-30) — Cash And Cash Equivalents: 87970000.00
JBIO balance_sheet (quarterly, 2024-09-30) — Cash Cash Equivalents And Short Term Investments: 87970000.00
JBIO balance_sheet (quarterly, 2024-09-30) — Cash Financial: 87970000.00
JBIO balance_sheet (quarterly, 2024-09-30) — Common Stock: 1000.00
JBIO balance_sheet (quarterly, 2024-09-30) — Common Stock Equity: -16863000.00
JBIO balance_sheet (quarterly, 2024-09-30) — Current Accrued Expenses: 8481000.00
JBIO balance_sheet (quarterly, 2024-09-30) — Current Assets: 88188000.00
JBIO balance_sheet (quarterly, 2024-09-30) — Current Liabilities: 9484000.00
JBIO balance_sheet (quarterly, 2024-09-30) — Derivative Product Liabilities: 24000.00
JBIO income_statement (quarterly, 2024-09-30) — Diluted Average Shares: 32235926.00
JBIO income_statement (quarterly, 2024-09-30) — Diluted EPS: -0.50
JBIO balance_sheet (quarterly, 2024-09-30) — Duefrom Related Parties Current: 0.00
JBIO balance_sheet (quarterly, 2024-09-30) — Invested Capital: 79837000.00
JBIO cash_flow (quarterly, 2024-09-30) — Issuance Of Debt: 95000000.00
JBIO balance_sheet (quarterly, 2024-09-30) — Long Term Debt: 96700000.00
JBIO balance_sheet (quarterly, 2024-09-30) — Long Term Debt And Capital Lease Obligation: 96700000.00
JBIO cash_flow (quarterly, 2024-09-30) — Long Term Debt Issuance: 95000000.00
JBIO balance_sheet (quarterly, 2024-09-30) — Net Debt: 8730000.00
JBIO cash_flow (quarterly, 2024-09-30) — Net Issuance Payments Of Debt: 95000000.00
JBIO cash_flow (quarterly, 2024-09-30) — Net Long Term Debt Issuance: 95000000.00
JBIO balance_sheet (quarterly, 2024-09-30) — Net Tangible Assets: -16863000.00
JBIO balance_sheet (quarterly, 2024-09-30) — Ordinary Shares Number: 32235926.00
JBIO balance_sheet (quarterly, 2024-09-30) — Other Current Assets: 218000.00
JBIO balance_sheet (quarterly, 2024-09-30) — Other Non Current Assets: 1159000.00
JBIO balance_sheet (quarterly, 2024-09-30) — Payables: 923000.00
JBIO balance_sheet (quarterly, 2024-09-30) — Payables And Accrued Expenses: 9404000.00
JBIO balance_sheet (quarterly, 2024-09-30) — Pensionand Other Post Retirement Benefit Plans Current: 80000.00
JBIO balance_sheet (quarterly, 2024-09-30) — Preferred Securities Outside Stock Equity: 2000.00
JBIO balance_sheet (quarterly, 2024-09-30) — Receivables: 0.00
JBIO balance_sheet (quarterly, 2024-09-30) — Retained Earnings: -16867000.00
JBIO balance_sheet (quarterly, 2024-09-30) — Share Issued: 32235926.00
JBIO balance_sheet (quarterly, 2024-09-30) — Stockholders Equity: -16863000.00
JBIO balance_sheet (quarterly, 2024-09-30) — Tangible Book Value: -16863000.00
JBIO balance_sheet (quarterly, 2024-09-30) — Total Assets: 89347000.00
JBIO balance_sheet (quarterly, 2024-09-30) — Total Capitalization: 79837000.00
JBIO balance_sheet (quarterly, 2024-09-30) — Total Debt: 96700000.00
JBIO balance_sheet (quarterly, 2024-09-30) — Total Equity Gross Minority Interest: -16863000.00
JBIO balance_sheet (quarterly, 2024-09-30) — Total Liabilities Net Minority Interest: 106210000.00
JBIO balance_sheet (quarterly, 2024-09-30) — Total Non Current Assets: 1159000.00
JBIO balance_sheet (quarterly, 2024-09-30) — Total Non Current Liabilities Net Minority Interest: 96726000.00
JBIO balance_sheet (quarterly, 2024-09-30) — Working Capital: 78704000.00
JBIO balance_sheet (annual, 2024-12-31) — Accounts Payable: 1290000.00
JBIO balance_sheet (annual, 2024-12-31) — Additional Paid In Capital: 179000.00
JBIO balance_sheet (annual, 2024-12-31) — Capital Lease Obligations: 0.00
JBIO balance_sheet (annual, 2024-12-31) — Capital Stock: 1000.00
JBIO balance_sheet (annual, 2024-12-31) — Cash And Cash Equivalents: 69386000.00
JBIO balance_sheet (annual, 2024-12-31) — Cash Cash Equivalents And Short Term Investments: 69386000.00
JBIO balance_sheet (annual, 2024-12-31) — Common Stock: 1000.00
JBIO balance_sheet (annual, 2024-12-31) — Common Stock Equity: -46799000.00
JBIO balance_sheet (annual, 2024-12-31) — Current Accrued Expenses: 6838000.00
JBIO balance_sheet (annual, 2024-12-31) — Current Assets: 69654000.00
JBIO balance_sheet (annual, 2024-12-31) — Current Liabilities: 11996000.00
JBIO balance_sheet (annual, 2024-12-31) — Gains Losses Not Affecting Retained Earnings: 0.00
JBIO balance_sheet (annual, 2024-12-31) — Gross PPE: 0.00
JBIO balance_sheet (annual, 2024-12-31) — Invested Capital: 60801000.00
JBIO cash_flow (quarterly, 2024-12-31) — Issuance Of Debt: 0.00
JBIO balance_sheet (annual, 2024-12-31) — Long Term Capital Lease Obligation: 0.00
JBIO balance_sheet (annual, 2024-12-31) — Long Term Debt: 107600000.00
JBIO balance_sheet (annual, 2024-12-31) — Long Term Debt And Capital Lease Obligation: 107600000.00
JBIO cash_flow (quarterly, 2024-12-31) — Long Term Debt Issuance: 0.00
JBIO balance_sheet (annual, 2024-12-31) — Net Debt: 38214000.00
JBIO cash_flow (quarterly, 2024-12-31) — Net Issuance Payments Of Debt: 0.00
JBIO cash_flow (quarterly, 2024-12-31) — Net Long Term Debt Issuance: 0.00
JBIO balance_sheet (annual, 2024-12-31) — Net PPE: 0.00
JBIO balance_sheet (annual, 2024-12-31) — Net Tangible Assets: -46799000.00
JBIO balance_sheet (annual, 2024-12-31) — Ordinary Shares Number: 32235926.00
JBIO balance_sheet (annual, 2024-12-31) — Other Current Assets: 268000.00
JBIO balance_sheet (annual, 2024-12-31) — Other Current Liabilities: 1077000.00
JBIO balance_sheet (annual, 2024-12-31) — Other Non Current Assets: 3145000.00
JBIO balance_sheet (annual, 2024-12-31) — Other Short Term Investments: 0.00
JBIO balance_sheet (annual, 2024-12-31) — Payables: 1290000.00
JBIO balance_sheet (annual, 2024-12-31) — Payables And Accrued Expenses: 8128000.00
JBIO balance_sheet (annual, 2024-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 2791000.00
JBIO balance_sheet (annual, 2024-12-31) — Preferred Securities Outside Stock Equity: 2000.00
JBIO balance_sheet (annual, 2024-12-31) — Preferred Stock: 0.00
JBIO balance_sheet (annual, 2024-12-31) — Retained Earnings: -46979000.00
JBIO balance_sheet (annual, 2024-12-31) — Share Issued: 32235926.00
JBIO balance_sheet (annual, 2024-12-31) — Stockholders Equity: -46799000.00
JBIO balance_sheet (annual, 2024-12-31) — Tangible Book Value: -46799000.00
JBIO balance_sheet (annual, 2024-12-31) — Total Assets: 72799000.00
JBIO balance_sheet (annual, 2024-12-31) — Total Capitalization: 60801000.00
JBIO balance_sheet (annual, 2024-12-31) — Total Debt: 107600000.00
JBIO balance_sheet (annual, 2024-12-31) — Total Equity Gross Minority Interest: -46799000.00
JBIO balance_sheet (annual, 2024-12-31) — Total Liabilities Net Minority Interest: 119598000.00
JBIO balance_sheet (annual, 2024-12-31) — Total Non Current Assets: 3145000.00
JBIO balance_sheet (annual, 2024-12-31) — Total Non Current Liabilities Net Minority Interest: 107602000.00
JBIO balance_sheet (annual, 2024-12-31) — Working Capital: 57658000.00
JBIO income_statement (quarterly, 2025-03-31) — +Operating Expense: 23384000.00
JBIO income_statement (quarterly, 2025-03-31) — +Total Revenue: 0.00
JBIO cash_flow (quarterly, 2025-03-31) — Amortization Of Securities: 0.00
JBIO income_statement (quarterly, 2025-03-31) — Basic Average Shares: 32235926.00
JBIO income_statement (quarterly, 2025-03-31) — Basic EPS: -1.18
JBIO cash_flow (quarterly, 2025-03-31) — Beginning Cash Position: 69386000.00
JBIO cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Financing Activities: -700000.00
JBIO cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Investing Activities: 0.00
JBIO cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Operating Activities: -18757000.00
JBIO cash_flow (quarterly, 2025-03-31) — Change In Account Payable: 2677000.00
JBIO cash_flow (quarterly, 2025-03-31) — Change In Accrued Expense: -538000.00
JBIO cash_flow (quarterly, 2025-03-31) — Change In Other Current Assets: -60000.00
JBIO cash_flow (quarterly, 2025-03-31) — Change In Other Current Liabilities: 9000.00
JBIO cash_flow (quarterly, 2025-03-31) — Change In Payable: 2677000.00
JBIO cash_flow (quarterly, 2025-03-31) — Change In Payables And Accrued Expense: 2139000.00
JBIO cash_flow (quarterly, 2025-03-31) — Change In Prepaid Assets: -507000.00
JBIO cash_flow (quarterly, 2025-03-31) — Change In Working Capital: 1581000.00
JBIO cash_flow (quarterly, 2025-03-31) — Changes In Cash: -19457000.00
JBIO cash_flow (quarterly, 2025-03-31) — Depreciation: 0.00
JBIO cash_flow (quarterly, 2025-03-31) — Depreciation Amortization Depletion: 0.00
JBIO cash_flow (quarterly, 2025-03-31) — Depreciation And Amortization: 0.00
JBIO income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 32235926.00
JBIO income_statement (quarterly, 2025-03-31) — Diluted EPS: -1.18
JBIO income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: -38169000.00
JBIO income_statement (quarterly, 2025-03-31) — EBIT: -23384000.00
JBIO income_statement (quarterly, 2025-03-31) — EBITDA: -23384000.00
JBIO cash_flow (quarterly, 2025-03-31) — Effect Of Exchange Rate Changes: 0.00
JBIO cash_flow (quarterly, 2025-03-31) — End Cash Position: 49929000.00
JBIO cash_flow (quarterly, 2025-03-31) — Financing Cash Flow: -700000.00
JBIO cash_flow (quarterly, 2025-03-31) — Free Cash Flow: -18757000.00
JBIO income_statement (quarterly, 2025-03-31) — General And Administrative Expense: 3361000.00
JBIO income_statement (quarterly, 2025-03-31) — Interest Income: 615000.00
JBIO income_statement (quarterly, 2025-03-31) — Interest Income Non Operating: 615000.00
JBIO cash_flow (quarterly, 2025-03-31) — Investing Cash Flow: 0.00
JBIO income_statement (quarterly, 2025-03-31) — Net Income: -38169000.00
JBIO income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: -38169000.00
JBIO income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: -38169000.00
JBIO income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: -38169000.00
JBIO income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: -38169000.00
JBIO cash_flow (quarterly, 2025-03-31) — Net Income From Continuing Operations: -38169000.00
JBIO income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: -38169000.00
JBIO income_statement (quarterly, 2025-03-31) — Net Interest Income: 615000.00
JBIO cash_flow (quarterly, 2025-03-31) — Net Investment Purchase And Sale: 0.00
JBIO income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: 615000.00
JBIO cash_flow (quarterly, 2025-03-31) — Net Other Financing Charges: -700000.00
JBIO income_statement (quarterly, 2025-03-31) — Normalized EBITDA: -23384000.00
JBIO income_statement (quarterly, 2025-03-31) — Normalized Income: -38169000.00
JBIO cash_flow (quarterly, 2025-03-31) — Operating Cash Flow: -18757000.00
JBIO income_statement (quarterly, 2025-03-31) — Operating Income: -23384000.00
JBIO income_statement (quarterly, 2025-03-31) — Operating Revenue: 0.00
JBIO income_statement (quarterly, 2025-03-31) — Other Gand A: 1648000.00
JBIO income_statement (quarterly, 2025-03-31) — Other Income Expense: -15400000.00
JBIO cash_flow (quarterly, 2025-03-31) — Other Non Cash Items: 15408000.00
JBIO income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: -15400000.00
JBIO income_statement (quarterly, 2025-03-31) — Pretax Income: -38169000.00
JBIO cash_flow (quarterly, 2025-03-31) — Proceeds From Stock Option Exercised: 0.00
JBIO cash_flow (quarterly, 2025-03-31) — Purchase Of Investment: 0.00
JBIO income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 0.00
JBIO income_statement (quarterly, 2025-03-31) — Research And Development: 20023000.00
JBIO income_statement (quarterly, 2025-03-31) — Salaries And Wages: 1713000.00
JBIO cash_flow (quarterly, 2025-03-31) — Sale Of Investment: 0.00
JBIO income_statement (quarterly, 2025-03-31) — Selling General And Administration: 3361000.00
JBIO cash_flow (quarterly, 2025-03-31) — Stock Based Compensation: 2423000.00
JBIO income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
JBIO income_statement (quarterly, 2025-03-31) — Tax Provision: 0.00
JBIO income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.00
JBIO income_statement (quarterly, 2025-03-31) — Total Expenses: 23384000.00
JBIO income_statement (quarterly, 2025-03-31) — Total Operating Income As Reported: -23384000.00
JBIO income_statement (quarterly, 2025-06-30) — +Operating Expense: 27778000.00
JBIO income_statement (quarterly, 2025-06-30) — +Total Revenue: 0.00
JBIO balance_sheet (quarterly, 2025-06-30) — Accounts Payable: 7586000.00
JBIO balance_sheet (quarterly, 2025-06-30) — Additional Paid In Capital: 318857000.00
JBIO income_statement (quarterly, 2025-06-30) — Basic Average Shares: 28431158.00
JBIO income_statement (quarterly, 2025-06-30) — Basic EPS: -0.86
JBIO cash_flow (quarterly, 2025-06-30) — Beginning Cash Position: 49929000.00
JBIO balance_sheet (quarterly, 2025-06-30) — Capital Lease Obligations: 792000.00
JBIO balance_sheet (quarterly, 2025-06-30) — Capital Stock: 5000.00
JBIO balance_sheet (quarterly, 2025-06-30) — Cash And Cash Equivalents: 220942000.00
JBIO balance_sheet (quarterly, 2025-06-30) — Cash Cash Equivalents And Short Term Investments: 220942000.00
JBIO cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Financing Activities: 191308000.00
JBIO cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Investing Activities: -136000.00
JBIO cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Operating Activities: -20159000.00
JBIO cash_flow (quarterly, 2025-06-30) — Change In Account Payable: 2261000.00
JBIO cash_flow (quarterly, 2025-06-30) — Change In Accrued Expense: 276000.00
JBIO cash_flow (quarterly, 2025-06-30) — Change In Other Current Assets: 148000.00
JBIO cash_flow (quarterly, 2025-06-30) — Change In Payable: 2261000.00
JBIO cash_flow (quarterly, 2025-06-30) — Change In Payables And Accrued Expense: 2537000.00
JBIO cash_flow (quarterly, 2025-06-30) — Change In Prepaid Assets: -851000.00
JBIO cash_flow (quarterly, 2025-06-30) — Change In Working Capital: 1825000.00
JBIO cash_flow (quarterly, 2025-06-30) — Changes In Cash: 171013000.00
JBIO balance_sheet (quarterly, 2025-06-30) — Common Stock: 3000.00
JBIO balance_sheet (quarterly, 2025-06-30) — Common Stock Equity: 201554000.00
JBIO balance_sheet (quarterly, 2025-06-30) — Current Accrued Expenses: 8686000.00
JBIO balance_sheet (quarterly, 2025-06-30) — Current Assets: 222984000.00
JBIO balance_sheet (quarterly, 2025-06-30) — Current Liabilities: 21620000.00
JBIO cash_flow (quarterly, 2025-06-30) — Depreciation: 5000.00
JBIO cash_flow (quarterly, 2025-06-30) — Depreciation Amortization Depletion: 5000.00
JBIO cash_flow (quarterly, 2025-06-30) — Depreciation And Amortization: 5000.00
JBIO income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 28431158.00
JBIO income_statement (quarterly, 2025-06-30) — Diluted EPS: -0.86
JBIO income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: -32134000.00
JBIO income_statement (quarterly, 2025-06-30) — EBIT: -27778000.00
JBIO income_statement (quarterly, 2025-06-30) — EBITDA: -27773000.00
JBIO cash_flow (quarterly, 2025-06-30) — End Cash Position: 220942000.00
JBIO cash_flow (quarterly, 2025-06-30) — Financing Cash Flow: 191308000.00
JBIO cash_flow (quarterly, 2025-06-30) — Free Cash Flow: -20295000.00
JBIO balance_sheet (quarterly, 2025-06-30) — Gains Losses Not Affecting Retained Earnings: -24000.00
JBIO income_statement (quarterly, 2025-06-30) — General And Administrative Expense: 5231000.00
JBIO balance_sheet (quarterly, 2025-06-30) — Gross PPE: 924000.00
JBIO income_statement (quarterly, 2025-06-30) — Interest Income: 1828000.00
JBIO income_statement (quarterly, 2025-06-30) — Interest Income Non Operating: 1828000.00
JBIO balance_sheet (quarterly, 2025-06-30) — Invested Capital: 201554000.00
JBIO cash_flow (quarterly, 2025-06-30) — Investing Cash Flow: -136000.00
JBIO balance_sheet (quarterly, 2025-06-30) — Long Term Capital Lease Obligation: 792000.00
JBIO balance_sheet (quarterly, 2025-06-30) — Long Term Debt And Capital Lease Obligation: 792000.00
JBIO income_statement (quarterly, 2025-06-30) — Net Income: -32134000.00
JBIO income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: -32134000.00
JBIO income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: -32134000.00
JBIO income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: -32134000.00
JBIO income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: -32134000.00
JBIO cash_flow (quarterly, 2025-06-30) — Net Income From Continuing Operations: -32134000.00
JBIO income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: -32134000.00
JBIO income_statement (quarterly, 2025-06-30) — Net Interest Income: 1828000.00
JBIO income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: 1828000.00
JBIO cash_flow (quarterly, 2025-06-30) — Net Other Financing Charges: 856000.00
JBIO balance_sheet (quarterly, 2025-06-30) — Net PPE: 924000.00
JBIO balance_sheet (quarterly, 2025-06-30) — Net Tangible Assets: 201556000.00
JBIO income_statement (quarterly, 2025-06-30) — Normalized EBITDA: -27773000.00
JBIO income_statement (quarterly, 2025-06-30) — Normalized Income: -32134000.00
JBIO cash_flow (quarterly, 2025-06-30) — Operating Cash Flow: -20159000.00
JBIO income_statement (quarterly, 2025-06-30) — Operating Income: -27778000.00
JBIO income_statement (quarterly, 2025-06-30) — Operating Revenue: 0.00
JBIO balance_sheet (quarterly, 2025-06-30) — Ordinary Shares Number: 32626730.00
JBIO balance_sheet (quarterly, 2025-06-30) — Other Current Assets: 2042000.00
JBIO balance_sheet (quarterly, 2025-06-30) — Other Current Liabilities: 3563000.00
JBIO balance_sheet (quarterly, 2025-06-30) — Other Equity Adjustments: -24000.00
JBIO income_statement (quarterly, 2025-06-30) — Other Gand A: 2113000.00
JBIO income_statement (quarterly, 2025-06-30) — Other Income Expense: -6184000.00
JBIO cash_flow (quarterly, 2025-06-30) — Other Non Cash Items: 6250000.00
JBIO balance_sheet (quarterly, 2025-06-30) — Other Non Current Assets: 60000.00
JBIO income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: -6184000.00
JBIO balance_sheet (quarterly, 2025-06-30) — Other Properties: 924000.00
JBIO balance_sheet (quarterly, 2025-06-30) — Payables: 7586000.00
JBIO balance_sheet (quarterly, 2025-06-30) — Payables And Accrued Expenses: 16272000.00
JBIO balance_sheet (quarterly, 2025-06-30) — Pensionand Other Post Retirement Benefit Plans Current: 1785000.00
JBIO balance_sheet (quarterly, 2025-06-30) — Preferred Securities Outside Stock Equity: 0.00
JBIO balance_sheet (quarterly, 2025-06-30) — Preferred Stock: 2000.00
JBIO balance_sheet (quarterly, 2025-06-30) — Preferred Stock Equity: 2000.00
JBIO income_statement (quarterly, 2025-06-30) — Pretax Income: -32134000.00
JBIO income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 5000.00
JBIO income_statement (quarterly, 2025-06-30) — Research And Development: 22547000.00
JBIO balance_sheet (quarterly, 2025-06-30) — Retained Earnings: -117282000.00
JBIO income_statement (quarterly, 2025-06-30) — Salaries And Wages: 3118000.00
JBIO income_statement (quarterly, 2025-06-30) — Selling General And Administration: 5231000.00
JBIO balance_sheet (quarterly, 2025-06-30) — Share Issued: 32626730.00
JBIO cash_flow (quarterly, 2025-06-30) — Stock Based Compensation: 3895000.00
JBIO balance_sheet (quarterly, 2025-06-30) — Stockholders Equity: 201556000.00
JBIO balance_sheet (quarterly, 2025-06-30) — Tangible Book Value: 201554000.00
JBIO income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 0.00
JBIO income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.00
JBIO balance_sheet (quarterly, 2025-06-30) — Total Assets: 223968000.00
JBIO balance_sheet (quarterly, 2025-06-30) — Total Capitalization: 201556000.00
JBIO balance_sheet (quarterly, 2025-06-30) — Total Debt: 792000.00
JBIO balance_sheet (quarterly, 2025-06-30) — Total Equity Gross Minority Interest: 201556000.00
JBIO income_statement (quarterly, 2025-06-30) — Total Expenses: 27778000.00
JBIO balance_sheet (quarterly, 2025-06-30) — Total Liabilities Net Minority Interest: 22412000.00
JBIO balance_sheet (quarterly, 2025-06-30) — Total Non Current Assets: 984000.00
JBIO balance_sheet (quarterly, 2025-06-30) — Total Non Current Liabilities Net Minority Interest: 792000.00
JBIO income_statement (quarterly, 2025-06-30) — Total Operating Income As Reported: -27778000.00
JBIO balance_sheet (quarterly, 2025-06-30) — Working Capital: 201364000.00
JBIO income_statement (quarterly, 2025-09-30) — +Operating Expense: 27401000.00
JBIO income_statement (quarterly, 2025-09-30) — +Total Revenue: 0.00
JBIO balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 1350000.00
JBIO balance_sheet (quarterly, 2025-09-30) — Additional Paid In Capital: 321769000.00
JBIO income_statement (quarterly, 2025-09-30) — Basic Average Shares: 39584489.00
JBIO income_statement (quarterly, 2025-09-30) — Basic EPS: -0.48
JBIO cash_flow (quarterly, 2025-09-30) — Beginning Cash Position: 220942000.00
JBIO cash_flow (quarterly, 2025-09-30) — Capital Expenditure: -57000.00
JBIO balance_sheet (quarterly, 2025-09-30) — Capital Lease Obligations: 747000.00
JBIO balance_sheet (quarterly, 2025-09-30) — Capital Stock: 5000.00
JBIO balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 50106000.00
JBIO balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 198905000.00
JBIO cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Financing Activities: 0.00
JBIO cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Investing Activities: -148708000.00
JBIO cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Operating Activities: -22124000.00
JBIO cash_flow (quarterly, 2025-09-30) — Change In Account Payable: -4878000.00
JBIO cash_flow (quarterly, 2025-09-30) — Change In Accrued Expense: 4246000.00
JBIO cash_flow (quarterly, 2025-09-30) — Change In Payable: -4878000.00
JBIO cash_flow (quarterly, 2025-09-30) — Change In Payables And Accrued Expense: -632000.00
JBIO cash_flow (quarterly, 2025-09-30) — Change In Prepaid Assets: -413000.00
JBIO cash_flow (quarterly, 2025-09-30) — Change In Working Capital: -1065000.00
JBIO cash_flow (quarterly, 2025-09-30) — Changes In Cash: -170832000.00
JBIO balance_sheet (quarterly, 2025-09-30) — Common Stock: 3000.00
JBIO balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 179344000.00
JBIO cash_flow (quarterly, 2025-09-30) — Common Stock Issuance: 0.00
JBIO balance_sheet (quarterly, 2025-09-30) — Current Accrued Expenses: 12956000.00
JBIO balance_sheet (quarterly, 2025-09-30) — Current Assets: 201360000.00
JBIO balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 22357000.00
JBIO cash_flow (quarterly, 2025-09-30) — Depreciation: 12000.00
JBIO cash_flow (quarterly, 2025-09-30) — Depreciation Amortization Depletion: 12000.00
JBIO cash_flow (quarterly, 2025-09-30) — Depreciation And Amortization: 12000.00
JBIO income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 39584489.00
JBIO income_statement (quarterly, 2025-09-30) — Diluted EPS: -0.48
JBIO income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: -25175000.00
JBIO income_statement (quarterly, 2025-09-30) — EBIT: -27401000.00
JBIO income_statement (quarterly, 2025-09-30) — EBITDA: -27389000.00
JBIO cash_flow (quarterly, 2025-09-30) — End Cash Position: 50106000.00
JBIO cash_flow (quarterly, 2025-09-30) — Financing Cash Flow: 0.00
JBIO cash_flow (quarterly, 2025-09-30) — Free Cash Flow: -22181000.00
JBIO balance_sheet (quarterly, 2025-09-30) — Gains Losses Not Affecting Retained Earnings: 29000.00
JBIO income_statement (quarterly, 2025-09-30) — General And Administrative Expense: 5391000.00
JBIO balance_sheet (quarterly, 2025-09-30) — Gross PPE: 916000.00
JBIO income_statement (quarterly, 2025-09-30) — Interest Income: 2254000.00
JBIO income_statement (quarterly, 2025-09-30) — Interest Income Non Operating: 2254000.00
JBIO balance_sheet (quarterly, 2025-09-30) — Invested Capital: 179344000.00
JBIO cash_flow (quarterly, 2025-09-30) — Investing Cash Flow: -148708000.00
JBIO cash_flow (quarterly, 2025-09-30) — Issuance Of Capital Stock: 0.00
JBIO balance_sheet (quarterly, 2025-09-30) — Long Term Capital Lease Obligation: 747000.00
JBIO balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 747000.00
JBIO cash_flow (quarterly, 2025-09-30) — Net Common Stock Issuance: 0.00
JBIO income_statement (quarterly, 2025-09-30) — Net Income: -25175000.00
JBIO income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: -25175000.00
JBIO income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: -25175000.00
JBIO income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: -25175000.00
JBIO income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: -25175000.00
JBIO cash_flow (quarterly, 2025-09-30) — Net Income From Continuing Operations: -25175000.00
JBIO income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: -25175000.00
JBIO income_statement (quarterly, 2025-09-30) — Net Interest Income: 2254000.00
JBIO income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: 2254000.00
JBIO cash_flow (quarterly, 2025-09-30) — Net Other Financing Charges: 0.00
JBIO balance_sheet (quarterly, 2025-09-30) — Net PPE: 916000.00
JBIO cash_flow (quarterly, 2025-09-30) — Net PPE Purchase And Sale: -57000.00
JBIO balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 179346000.00
JBIO income_statement (quarterly, 2025-09-30) — Normalized EBITDA: -27389000.00
JBIO income_statement (quarterly, 2025-09-30) — Normalized Income: -25175000.00
JBIO cash_flow (quarterly, 2025-09-30) — Operating Cash Flow: -22124000.00
JBIO income_statement (quarterly, 2025-09-30) — Operating Income: -27401000.00
JBIO income_statement (quarterly, 2025-09-30) — Operating Revenue: 0.00
JBIO balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 32626730.00
JBIO balance_sheet (quarterly, 2025-09-30) — Other Current Assets: 2455000.00
JBIO balance_sheet (quarterly, 2025-09-30) — Other Current Liabilities: 4947000.00
JBIO balance_sheet (quarterly, 2025-09-30) — Other Equity Adjustments: 29000.00
JBIO income_statement (quarterly, 2025-09-30) — Other Gand A: 1806000.00
JBIO income_statement (quarterly, 2025-09-30) — Other Income Expense: -28000.00
JBIO cash_flow (quarterly, 2025-09-30) — Other Non Cash Items: -17000.00
JBIO balance_sheet (quarterly, 2025-09-30) — Other Non Current Assets: 174000.00
JBIO income_statement (quarterly, 2025-09-30) — Other Non Operating Income Expenses: -28000.00
JBIO balance_sheet (quarterly, 2025-09-30) — Other Properties: 916000.00
JBIO balance_sheet (quarterly, 2025-09-30) — Other Short Term Investments: 148799000.00
JBIO balance_sheet (quarterly, 2025-09-30) — Payables: 1350000.00
JBIO balance_sheet (quarterly, 2025-09-30) — Payables And Accrued Expenses: 14306000.00
JBIO balance_sheet (quarterly, 2025-09-30) — Pensionand Other Post Retirement Benefit Plans Current: 3104000.00
JBIO balance_sheet (quarterly, 2025-09-30) — Preferred Securities Outside Stock Equity: 0.00
JBIO balance_sheet (quarterly, 2025-09-30) — Preferred Stock: 2000.00
JBIO balance_sheet (quarterly, 2025-09-30) — Preferred Stock Equity: 2000.00
JBIO income_statement (quarterly, 2025-09-30) — Pretax Income: -25175000.00
JBIO cash_flow (quarterly, 2025-09-30) — Purchase Of PPE: -57000.00
JBIO income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 12000.00
JBIO income_statement (quarterly, 2025-09-30) — Research And Development: 22010000.00
JBIO balance_sheet (quarterly, 2025-09-30) — Retained Earnings: -142457000.00
JBIO income_statement (quarterly, 2025-09-30) — Salaries And Wages: 3585000.00
JBIO income_statement (quarterly, 2025-09-30) — Selling General And Administration: 5391000.00
JBIO balance_sheet (quarterly, 2025-09-30) — Share Issued: 32626730.00
JBIO cash_flow (quarterly, 2025-09-30) — Stock Based Compensation: 4295000.00
JBIO balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 179346000.00
JBIO balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 179344000.00
JBIO income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: 0.00
JBIO income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.00
JBIO balance_sheet (quarterly, 2025-09-30) — Total Assets: 202450000.00
JBIO balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 179346000.00
JBIO balance_sheet (quarterly, 2025-09-30) — Total Debt: 747000.00
JBIO balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 179346000.00
JBIO income_statement (quarterly, 2025-09-30) — Total Expenses: 27401000.00
JBIO balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 23104000.00
JBIO balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 1090000.00
JBIO balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 747000.00
JBIO income_statement (quarterly, 2025-09-30) — Total Operating Income As Reported: -27401000.00
JBIO balance_sheet (quarterly, 2025-09-30) — Working Capital: 179003000.00
JBIO income_statement (annual, 2025-12-31) — +Operating Expense: 113542000.00
JBIO income_statement (quarterly, 2025-12-31) — +Operating Expense: 34979000.00
JBIO income_statement (annual, 2025-12-31) — +Total Revenue: 0.00
JBIO income_statement (quarterly, 2025-12-31) — +Total Revenue: 0.00
JBIO balance_sheet (annual, 2025-12-31) — Accounts Payable: 2151000.00
JBIO balance_sheet (quarterly, 2025-12-31) — Accounts Payable: 2151000.00
JBIO balance_sheet (annual, 2025-12-31) — Additional Paid In Capital: 506771000.00
JBIO balance_sheet (quarterly, 2025-12-31) — Additional Paid In Capital: 506771000.00
JBIO cash_flow (annual, 2025-12-31) — Amortization Of Securities: -784000.00
JBIO cash_flow (quarterly, 2025-12-31) — Amortization Of Securities: -610000.00
JBIO income_statement (annual, 2025-12-31) — Basic Average Shares: 31359958.00
JBIO income_statement (annual, 2025-12-31) — Basic EPS: -3.19
JBIO cash_flow (annual, 2025-12-31) — Beginning Cash Position: 69386000.00
JBIO cash_flow (quarterly, 2025-12-31) — Beginning Cash Position: 50106000.00
JBIO cash_flow (annual, 2025-12-31) — Capital Expenditure: -196000.00
JBIO cash_flow (quarterly, 2025-12-31) — Capital Expenditure: -3000.00
JBIO balance_sheet (annual, 2025-12-31) — Capital Lease Obligations: 724000.00
JBIO balance_sheet (quarterly, 2025-12-31) — Capital Lease Obligations: 724000.00
JBIO balance_sheet (annual, 2025-12-31) — Capital Stock: 7000.00
JBIO balance_sheet (quarterly, 2025-12-31) — Capital Stock: 7000.00
JBIO balance_sheet (annual, 2025-12-31) — Cash And Cash Equivalents: 88438000.00
JBIO balance_sheet (quarterly, 2025-12-31) — Cash And Cash Equivalents: 88438000.00
JBIO balance_sheet (annual, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 336158000.00
JBIO balance_sheet (quarterly, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 336158000.00
JBIO cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Financing Activities: 360768000.00
JBIO cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Financing Activities: 170160000.00
JBIO cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Investing Activities: -247006000.00
JBIO cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Investing Activities: -98162000.00
JBIO cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Operating Activities: -94689000.00
JBIO cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Operating Activities: -33649000.00
JBIO cash_flow (annual, 2025-12-31) — Change In Account Payable: 361000.00
JBIO cash_flow (quarterly, 2025-12-31) — Change In Account Payable: 301000.00
JBIO cash_flow (annual, 2025-12-31) — Change In Accrued Expense: 3409000.00
JBIO cash_flow (quarterly, 2025-12-31) — Change In Accrued Expense: -575000.00
JBIO cash_flow (annual, 2025-12-31) — Change In Other Current Assets: -38000.00
JBIO cash_flow (annual, 2025-12-31) — Change In Other Current Liabilities: 40000.00
JBIO cash_flow (quarterly, 2025-12-31) — Change In Other Current Liabilities: -28000.00
JBIO cash_flow (annual, 2025-12-31) — Change In Payable: 361000.00
JBIO cash_flow (quarterly, 2025-12-31) — Change In Payable: 301000.00
JBIO cash_flow (annual, 2025-12-31) — Change In Payables And Accrued Expense: 3770000.00
JBIO cash_flow (quarterly, 2025-12-31) — Change In Payables And Accrued Expense: -274000.00
JBIO cash_flow (annual, 2025-12-31) — Change In Prepaid Assets: -11969000.00
JBIO cash_flow (quarterly, 2025-12-31) — Change In Prepaid Assets: -10198000.00
JBIO cash_flow (annual, 2025-12-31) — Change In Working Capital: -8197000.00
JBIO cash_flow (quarterly, 2025-12-31) — Change In Working Capital: -10538000.00
JBIO cash_flow (annual, 2025-12-31) — Changes In Cash: 19073000.00
JBIO cash_flow (quarterly, 2025-12-31) — Changes In Cash: 38349000.00
JBIO balance_sheet (annual, 2025-12-31) — Common Stock: 5000.00
JBIO balance_sheet (quarterly, 2025-12-31) — Common Stock: 5000.00
JBIO balance_sheet (annual, 2025-12-31) — Common Stock Equity: 332516000.00
JBIO balance_sheet (quarterly, 2025-12-31) — Common Stock Equity: 332516000.00
JBIO cash_flow (annual, 2025-12-31) — Common Stock Issuance: 189111000.00
JBIO cash_flow (quarterly, 2025-12-31) — Common Stock Issuance: -1341000.00
JBIO balance_sheet (annual, 2025-12-31) — Current Accrued Expenses: 11065000.00
JBIO balance_sheet (quarterly, 2025-12-31) — Current Accrued Expenses: 11065000.00
JBIO balance_sheet (annual, 2025-12-31) — Current Assets: 348816000.00
JBIO balance_sheet (quarterly, 2025-12-31) — Current Assets: 348816000.00
JBIO balance_sheet (annual, 2025-12-31) — Current Liabilities: 16539000.00
JBIO balance_sheet (quarterly, 2025-12-31) — Current Liabilities: 16539000.00
JBIO cash_flow (annual, 2025-12-31) — Depreciation: 26000.00
JBIO cash_flow (quarterly, 2025-12-31) — Depreciation: 9000.00
JBIO cash_flow (annual, 2025-12-31) — Depreciation Amortization Depletion: 26000.00
JBIO cash_flow (quarterly, 2025-12-31) — Depreciation Amortization Depletion: 9000.00
JBIO cash_flow (annual, 2025-12-31) — Depreciation And Amortization: 26000.00
JBIO cash_flow (quarterly, 2025-12-31) — Depreciation And Amortization: 9000.00
JBIO income_statement (annual, 2025-12-31) — Diluted Average Shares: 31359958.00
JBIO income_statement (annual, 2025-12-31) — Diluted EPS: -3.19
JBIO income_statement (annual, 2025-12-31) — Diluted NI Availto Com Stockholders: -127410000.00
JBIO income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: -31932000.00
JBIO income_statement (annual, 2025-12-31) — EBIT: -113542000.00
JBIO income_statement (quarterly, 2025-12-31) — EBIT: -34979000.00
JBIO income_statement (annual, 2025-12-31) — EBITDA: -113516000.00
JBIO income_statement (quarterly, 2025-12-31) — EBITDA: -34970000.00
JBIO cash_flow (annual, 2025-12-31) — Effect Of Exchange Rate Changes: -21000.00
JBIO cash_flow (quarterly, 2025-12-31) — Effect Of Exchange Rate Changes: -17000.00
JBIO cash_flow (annual, 2025-12-31) — End Cash Position: 88438000.00
JBIO cash_flow (quarterly, 2025-12-31) — End Cash Position: 88438000.00
JBIO cash_flow (annual, 2025-12-31) — Financing Cash Flow: 360768000.00
JBIO cash_flow (quarterly, 2025-12-31) — Financing Cash Flow: 170160000.00
JBIO cash_flow (annual, 2025-12-31) — Free Cash Flow: -94885000.00
JBIO cash_flow (quarterly, 2025-12-31) — Free Cash Flow: -33652000.00
JBIO balance_sheet (annual, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: 129000.00
JBIO balance_sheet (quarterly, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: 129000.00
JBIO income_statement (annual, 2025-12-31) — General And Administrative Expense: 20421000.00
JBIO income_statement (quarterly, 2025-12-31) — General And Administrative Expense: 6438000.00
JBIO balance_sheet (annual, 2025-12-31) — Gross PPE: 896000.00